نتایج جستجو برای: a9 everolimus stents drug

تعداد نتایج: 602739  

2013
Matthew G. Whitbeck Robert J. Applegate

Everolimus-eluting stents (EES) represent the next generation of drug-eluting stents (DES). Important design modifications include thin strut stent backbones, less inflammatory and more biocompatible polymers, and lower drug dosing. The cobalt chromium EES fluoropolymer XIENCE V stent has been the most extensively studied of such stents. In animal models, this stent demonstrated minimal vessel ...

2011
Masato Nakamura

Drug-eluting stents have been demonstrated to improve outcomes for coronary artery disease patients. Introduction of the new-generation everolimus-eluting stent into Japanese clinical practice has raised expectations of further enhancement in the field of percutaneous coronary intervention. This article will evaluate this device by systematically reviewing its mechanical characteristics and ass...

Journal: :Circulation. Cardiovascular interventions 2015
Javaid Iqbal Patrick W Serruys Sigmund Silber Henning Kelbaek Gert Richardt Marie-Angele Morel Manuela Negoita Pawel E Buszman Stephan Windecker

BACKGROUND Newer-generation drug-eluting stents that release zotarolimus or everolimus have been shown to be superior to the first-generation drug-eluting stents. However, data comparing long-term safety and efficacy of zotarolimus- (ZES) and everolimus-eluting stents (EES) are limited. RESOLUTE all-comers (Randomized Comparison of a Zotarolimus-Eluting Stent With an Everolimus-Eluting Stent fo...

Journal: :Revista espanola de cardiologia 2013
Rafael J Ruiz-Salmerón Luis F Valenzuela Inés Pérez Marco Fuentes Sergio Rodríguez-Leiras Manuel Vizcaíno César Carrascosa Francisco Marcos

INTRODUCTION AND OBJECTIVES Coronary bifurcation lesions can be approached using a simple or a complex strategy. In clinical trials with first-generation drug-eluting stents, the complex strategy was not superior to the simple approach. However, to date, the best strategy when using second-generation drug-eluting stents has not been defined. METHODS We performed a prospective randomized study...

Journal: :The New England journal of medicine 2016
Eric R Bates

BACKGROUND Limited data are available on the long-term effects of contemporary drug-eluting stents versus contemporary bare-metal stents on rates of death, myocardial infarction, repeat revascularization, and stent thrombosis and on quality of life. METHODS We randomly assigned 9013 patients who had stable or unstable coronary artery disease to undergo percutaneous coronary intervention (PCI)...

2005
SIGMUND SILBER

Today, drug-eluting stents (DES) are the standard stenting procedure in the USA and in Switzerland. The objective of this analysis is to answer the two questions: what clinically relevant data regarding DES have been published, and is there a clinically relevant difference between the Cypher and the Taxus stents? Twenty-two randomized, controlled studies with a total of 11,118 patients were ide...

2013
Johan Bennett Christophe Dubois

The development of coronary stents represents a major step forward in the treatment of obstructive coronary artery disease since the introduction of percutaneous coronary intervention. The initial enthusiasm for bare metal stents was, however, tempered by a significant incidence of in-stent restenosis, the manifestation of excessive neointima hyperplasia within the stented vessel segment, ultim...

Journal: :Circulation. Cardiovascular interventions 2013
Raul Moreno Eulogio García Rui Teles Jose-Ramon Rumoroso Henrique Cyrne Carvalho Francisco Javier Goicolea José Moreu Josefa Mauri Manel Sabaté Vicente Mainar Lino Patricio Mariano Valdés Felipez Fernández Vázquez Angel Sánchez-Recalde Guillermo Galeote Santiago Jimenez-Valero Manuel Almeida Esteban Lopez de Sa Luis Calvo Ignacio Plaza Jose-Luis Lopez-Sendón Jose-Luis R Martín

BACKGROUND Patients with coronary total occlusions are at especially high risk for restenosis and new revascularizations. Sirolimus-eluting stents dramatically improved the clinical outcome of this subset of patients in randomized trials, but other drug-eluting stents, mainly the everolimus-eluting stent (currently the most frequently used stent), have not yet been evaluated in patients with co...

Journal: :European heart journal 2010
Giovanni G Camici Jan Steffel Ilijana Amanovic Alexander Breitenstein Janette Baldinger Stephan Keller Thomas F Lüscher Felix C Tanner

AIMS Drug-eluting stents (DES) may be associated with an increased risk for stent thrombosis when compared with bare-metal stents. In endothelial cells, rapamycin induces tissue factor (TF) by inhibiting the mammalian target of rapamycin (mTOR). However, the effect of mTOR inhibition on TF activity and thrombus formation in vivo has not yet been studied. Moreover, it is unclear whether second-g...

2011
Mahesh Bikkina Jayanth Koneru

The root cause of coronary artery disease is atherosclerosis, ie, intraluminal narrowing (stenosis) of the arteries that supply blood to tissues of the heart. The introduction of the drug-eluting stent over the past decade has revolutionized the field of interventional cardiology. It is used extensively in clinical practice for the treatment of coronary artery disease. The first drug-eluting st...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید